<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880213</url>
  </required_header>
  <id_info>
    <org_study_id>MS200569_0005</org_study_id>
    <secondary_id>2020-005408-20</secondary_id>
    <nct_id>NCT04880213</nct_id>
  </id_info>
  <brief_title>Study of M5049 in Healthy Japanese and Caucasian Participants</brief_title>
  <official_title>A Phase I, Open-label, Single-dose, Sequential Dose Group Study of Orally Administered M5049 Tablet Formulation in Healthy Japanese and Caucasian Participants to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and determine the safety, tolerability and&#xD;
      pharmacokinetics of single-doses of M5049 up to 3 dose levels administered as film-coated&#xD;
      tablet under fasted conditions in healthy Japanese and Caucasian participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Actual">September 10, 2021</completion_date>
  <primary_completion_date type="Actual">September 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (tlast) (AUC0-tlast) of M5049</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC0-inf) of M5049</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of M5049</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death</measure>
    <time_frame>Baseline up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Clinically Significant Changes from Baseline in Laboratory Parameters</measure>
    <time_frame>Baseline up to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Clinically Significant Changes from Baseline in Vital Signs</measure>
    <time_frame>Baseline up to Day 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Clinically Significant Changes from Baseline in 12-lead Electrocardiogram (ECGs) Findings</measure>
    <time_frame>Baseline up to Day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to 48 Hours Post-dose (AUC0-48) of M5049</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (tmax) of M5049</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t1/2) of M5049</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance (CL/f) of M5049</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/f) During Terminal Phase of M5049</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Japanese: M5049 Dose A (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese: M5049 Dose B (medium dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese: M5049 Dose C (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian: M5049 Dose A (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian: M5049 Dose B (medium dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Caucasian: M5049 Dose C (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M5049</intervention_name>
    <description>Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.</description>
    <arm_group_label>Caucasian: M5049 Dose A (low dose)</arm_group_label>
    <arm_group_label>Japanese: M5049 Dose A (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M5049</intervention_name>
    <description>Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.</description>
    <arm_group_label>Caucasian: M5049 Dose B (medium dose)</arm_group_label>
    <arm_group_label>Japanese: M5049 Dose B (medium dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M5049</intervention_name>
    <description>Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.</description>
    <arm_group_label>Caucasian: M5049 Dose C (high dose)</arm_group_label>
    <arm_group_label>Japanese: M5049 Dose C (high dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese participants must be first generation (born in Japan) with both biological&#xD;
             parents and all 4 biological grandparents being Japanese native born. Caucasian&#xD;
             participants must have both biological parents and 4 biological grandparents of&#xD;
             Caucasian descent&#xD;
&#xD;
          -  Overtly healthy participants as determined by medical evaluation, including medical&#xD;
             history, physical examination, laboratory tests, and cardiac monitoring (blood&#xD;
             pressure, heart rate and 12-Lead resting ECG)&#xD;
&#xD;
          -  Participants with body weight within 45 to 90 kilograms (kg) (female) and 55 to 90 kg&#xD;
             (male) and body mass index (BMI) between 18.5 and 29.9 kilograms per meter square&#xD;
             (kg/m^2)&#xD;
&#xD;
          -  A Caucasian participant will be matched by body weight (± 20% body weight [kg]),&#xD;
             height (± 15% height [centimeter (cm) ]) and sex to each Japanese participant&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with history of clinically relevant disease of any organ system that may&#xD;
             interfere with the objectives of the study or provide a risk to the health of the&#xD;
             participant&#xD;
&#xD;
          -  Participants with history of relevant drug hypersensitivity&#xD;
&#xD;
          -  Participants with history of splenectomy, epilepsy, other neurological disorders or&#xD;
             neuropsychiatric conditions&#xD;
&#xD;
          -  Participants with history of a tuberculosis and positive Screening test for hepatitis&#xD;
             B surface antigen&#xD;
&#xD;
          -  Participants with history of alcoholism or drug abuse&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Ltd.</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200569_0005</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>M5049</keyword>
  <keyword>Japanese</keyword>
  <keyword>Caucasian</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.merckgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

